Corbus Pharmaceuticals Holdings, Inc.
CRBP
Rank in Stocks
#21412
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in... Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFΓ expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Share Price
$3.52
Last synced: 2026-11-09
Market Cap
$68.08M
Change (1 day)
14.66%
Change (1 year)
-66.22%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Category
Healthcare
Operating Margin for Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Operating Margin as of November 2026 TTM: 0.00%
According to Corbus Pharmaceuticals Holdings, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Corbus Pharmaceuticals Holdings, Inc. from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | -100.00% |
| 2021 | -6,350.09% | 103.58% |
| 2020 | -3,119.20% | 1,362.15% |
| 2019 | -213.33% | -81.87% |
| 2018 | -1,176.78% | -11.81% |
| 2017 | -1,334.43% | 27.63% |
| 2016 | -1,045.56% | -23.43% |
| 2015 | -1,365.51% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Corbus Pharmaceuticals Holdings, Inc.'s operating margin
What was Corbus Pharmaceuticals Holdings, Inc.'s operating margin in 2025?
In 2025, Corbus Pharmaceuticals Holdings, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Corbus Pharmaceuticals Holdings, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Corbus Pharmaceuticals Holdings, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2021 (-6,350.09%).
How does Corbus Pharmaceuticals Holdings, Inc.'s operating margin compare with similar companies?
Corbus Pharmaceuticals Holdings, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.